10-Q quarterly report · filed Nov 9, 2026

Orthofix Medical Inc. (OFIX) Q3 2026 10-Q Quarterly Report

Short answer

Orthofix Medical Inc. (OFIX) filed its Q3 2026 10-Q quarterly report on Nov 9, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $208M (up 1.1% year over year) with net income of −$6M.

Q3 2026 key financials · XBRL

Revenue
$208M
+1.1% YoY · −1.5% QoQ
Net income
−$6M
+73.4% YoY · +61.6% QoQ
Operating margin
0.7%
Gross margin
70.5%
EPS (diluted)
−$0.15
+73.7% YoY · +60.5% QoQ

Source: XBRL data from the Orthofix Medical Inc. (OFIX) Q3 2026 10-Q on SEC EDGAR. USD.

Orthofix Medical Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $207.9M, up 1.1% YoY from $205.6M
  • Operating margin 0.7% vs (8.3%) YoY, net loss margin (2.9%) vs (11.1%)
  • Best segment Global Limb Reconstruction, $36.4M, up 8.5%; worst Spinal Implants, Biologics and Enabling Technologies, $107.4M, down 1.1%
  • Cash $86.9M vs $85.1M at December 31, 2025; nine-month operating cash flow $(23.5)M
  • $65.0M Term B Loan funded; FDA reclassification headwind, heightened competition and pricing pressure for bone stimulators

Risk Factors

  • Regulatory risk: FDA reclassification from Class III to Class II lowers entry barriers for bone growth stimulators
  • Competitive risk: New entrants could create pricing pressure and erode Orthofix’s market share
  • Operating risk: Higher research, clinical, marketing, and surveillance spending could reduce margins
  • Market risk: Increased competitor promotion could reduce demand for Orthofix products

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Orthofix Medical Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.